Proactive Investors - Run By Investors For Investors

Instem performing well; SEND platform stars

The company has developed software used by the life sciences industry to collate and transmit data
Instem performing well; SEND platform stars
SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration

Instem Plc (LON:INS), the developer of software used by the life sciences industry to collate and transmit data, said first-half trading was in line with market expectations.

The highlight was the performance of its SEND platform, with the value of contracts won thus far in 2018 exceeding the total for all of last year.

In all, it had 103 orders in the first six months from 50 different clients.

Instem said the contracted value of the SEND-related new business was up 190% year-on-year, while the pipeline continues to grow, driven by the US Food & Drug Administration’s investigational new drug rules.

SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration. It ensures that companies present data in a consistent format.

Sending the right message

It said a further shift towards providing its software as a service (rather than making one-off sales), combined with “increasingly material recurring outsourced services revenue”, will see a continued improvement of earnings visibility.

Both its Provantis and Samarind products are accessible via the cloud.

Financially, Instem has a solid base with net cash of £3.7mln at June 30.

"The financial year has started well and we are confident further new business, the delivery of recent contract wins and strong operational management will ensure we meet our expectations for the full year," said chief executive Phil Reason.

Shares more than double in value

The shares, which have more than doubled in value in the year to date, rise 7% in morning trade to change hands for 315p. This values the business at £50mln.

In a note to clients, Progressive Equity said: “In our view, the overall tone of the update is optimistic and the outlook statement positive.”

View full INS profile View Profile

Instem Plc Timeline

Related Articles

Financial chart
August 19 2018
The portfolio analytics platform operator has been shrewd in its acquisition policy and the purchase of Delta from UBS may just be the best acquisition yet
mobile payment
June 22 2018
MySQUAR wants to beef up the mobile payments side of its operations in anticipation of a surge in demand for those services in a country where only 20% of the adult population have a bank account
Apps on a smartphone
July 06 2018
“As of today, appScatter tracks 1.2bln app URLs, from 10.7mln apps and 2.9mln publishers,” chairman Clive Carver told shareholders at the AGM in June

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use